Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2022-03-29 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2021 by 华兰生物工程股份有限公司. It discusses the company's internal control evaluation, including financial and non-financial internal control effectiveness, governance structure, risk management, and compliance with regulatory requirements. The document contains detailed descriptions of internal control frameworks, evaluation standards, and conclusions about the absence of major deficiencies. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The content aligns with an Audit Report / Information filing, which covers audit results, applied accounting principles, and internal control assessments but is distinct from a full Annual Report (10-K). The document length (6642 characters) and detailed content support classification as AR rather than a brief announcement or regulatory filing. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2021
2022-03-29 Chinese
2021年社会责任报告
Environmental & Social Information Classification · 95% confidence The document is titled as a "2021 Annual Social Responsibility Report" of 华兰生物工程股份有限公司. It extensively discusses the company's social responsibility activities, environmental protection efforts, employee and stakeholder rights, and community engagement for the year 2021. The content focuses on Environmental, Social, and Governance (ESG) factors and sustainability initiatives rather than financial performance or regulatory filings. There is no indication that this is an announcement or a brief summary; it is a full report dedicated to social responsibility. Therefore, the document fits the category of Environmental & Social Information (SR). The document length (7,565 characters) supports it being a full report rather than a brief announcement.
2022-03-29 Chinese
华兰生物工程股份有限公司章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 华兰生物工程股份有限公司 dated March 2022. It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, management, financial accounting, profit distribution, and other governance matters. It is a comprehensive internal governance document that sets out the rules and regulations for the company's operation and management. This type of document corresponds to Governance Information (CGR) as it details the company's internal rules, board structure, and governance practices. It is not an announcement, report, or financial statement, but the company's bylaws themselves.
2022-03-29 Chinese
年度股东大会通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2021 Annual General Meeting (AGM) of 华兰生物工程股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), agenda items including board and supervisory reports, financial reports, profit distribution proposals, election of directors and supervisors, and amendments to company bylaws. It also contains instructions for shareholders on registration and proxy voting. The document is not the actual annual report or financial statements but rather the official notification and materials related to the AGM. This fits the definition of 'AGM Information' (AGM-R), which covers presentations and materials shared during the AGM. The document length is substantial (9408 characters), and it is not merely an announcement of a report publication but the full notice and agenda for the AGM.
2022-03-29 Chinese
2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2021 Annual Report Summary" of 华兰生物工程股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2021, including revenue, net profit, assets, and quarterly breakdowns. It also includes company business descriptions, product information, shareholder data, and corporate developments during the year. The length of the document (11,354 characters) and the presence of substantive financial and operational data confirm it is a full report rather than a brief announcement or certification. The document is clearly an official yearly report covering company activity and full financial performance, matching the definition of an Annual Report (10-K). FY 2021
2022-03-29 Chinese
2021年独立董事年度述职报告(王云龙)
Management Reports Classification · 95% confidence The document is a detailed report by an independent director of a company for the year 2021. It includes descriptions of the director's attendance at meetings, independent opinions on various company matters such as related party transactions, internal control evaluation, appointment of auditors, investment activities, profit distribution plans, and other governance-related issues. The document is titled as an "Independent Director 2021 Annual Report" and contains substantive content about the director's duties and opinions over the fiscal year. It is not a brief announcement or a certification letter but a comprehensive report on the independent director's activities and opinions for the year. This fits the category of a Management Report (MDA), which includes management's detailed explanation of business trends, governance, and outlook. The length (6724 characters) and content confirm it is a full report rather than an announcement or a short statement.
2022-03-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.